Patents by Inventor Lonnie L. BOOKBINDER

Lonnie L. BOOKBINDER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CANCER TREATMENT USING siRNA TO MODULATE EXPRESSION OF PRDM2/RIZ PROTEIN
    Publication number: 20240360445
    Abstract: Inhibitory RNA molecules that specifically inhibit mammalian RIZ2 expression, with therapeutic effect in cell proliferative diseases, such as cancer.
    Type: Application
    Filed: April 23, 2024
    Publication date: October 31, 2024
    Inventors: Lonnie L. BOOKBINDER, Narendra K. VAISH, Brad J. NILES, Jonathan FLYNN, Nicole NUNEZ
  • Cancer treatment using siRNA to modulate expression of PRDM2/RIZ protein
    Patent number: 12012597
    Abstract: Inhibitory RNA molecules that specifically inhibit mammalian RIZ2 expression, with therapeutic effect in cell proliferative diseases, such as cancer.
    Type: Grant
    Filed: September 15, 2022
    Date of Patent: June 18, 2024
    Assignee: ARIZ Precision Medicine, Inc.
    Inventors: Lonnie L. Bookbinder, Narendra K. Vaish, Brad J. Niles, Jonathan Flynn, Nicole Nunez
  • CANCER TREATMENT USING siRNA TO MODULATE EXPRESSION OF PRDM2/RIZ PROTEIN
    Publication number: 20230099879
    Abstract: Inhibitory RNA molecules that specifically inhibit mammalian RIZ2 expression, with therapeutic effect in cell proliferative diseases, such as cancer.
    Type: Application
    Filed: September 15, 2022
    Publication date: March 30, 2023
    Inventors: Lonnie L. BOOKBINDER, Narendra K. VAISH, Brad J. NILES, Jonathan FLYNN, Nicole NUNEZ
  • CANCER TREATMENT USING TARGETED siRNA PHARMACEUTICAL FORMULATIONS TO DOWNREGULATE EXPRESSION OF PRDM14 PROTEIN
    Publication number: 20220267775
    Abstract: Pharmaceutical formulations for the treatment of cancer comprising novel siRNAs that downregulate expression of the PRDM oncoprotein gene and inhibit tumor growth. siRNAs designed and selected to destroy PRDM14 mRNA are described. The siRNAs are delivered via one or more targeted drug delivery systems equipped with a tumor-specific targeting ligand that confers specific binding of the nanoparticle with siRNA payload to receptors on the surface of tumor cells.
    Type: Application
    Filed: January 7, 2022
    Publication date: August 25, 2022
    Inventors: Lonnie L. BOOKBINDER, Brad NILE, Nicole NUNEZ, Nicole HALMAI, Narendra K. VAISH